University of Virginia

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Virginia sits in the top decile of US sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count).

449 total trials 101 currently recruiting 281 completed early-phase tilt top decile by trial count

University of Virginia: 449 sponsored US clinical trials, 101 recruiting.

University of Virginia sponsors 449 registered US clinical trials on ClinicalTrials.gov, 101 of them currently recruiting, and 281 completed. 40 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 9 trials.

Top-decile sponsor footprint

University of Virginia ranks in the top decile of sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 61/100

281 of 317 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

449 total, page 7 of 9

COMPLETED Phase 1

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

NCT02335099

COMPLETED

The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans

NCT02490124

COMPLETED NA

Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery

NCT02058979

COMPLETED NA

The Impact of Riboflavin on the Severity and Duration of Sports Related Concussion

NCT02235337

COMPLETED NA

VentFirst Pilot: Ventilating Preterm Infants During Delayed Cord Clamping

NCT02391389

COMPLETED

A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer

NCT02239328

TERMINATED NA

Comprehensive Magnetic Resonance in Peripheral Arterial Disease.3

NCT02388685

COMPLETED NA

Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome

NCT02633488

COMPLETED NA

USS Virginia Closed-Loop for Overnight Control in Type 1 Diabetes

NCT02131766

COMPLETED

The Use of Near Infrared Spectroscopy (NIRS) to Estimate Intracranial Pressure (ICP)

NCT01850069

COMPLETED NA

Microvascular Disease Exercise Trial

NCT02045459

COMPLETED NA

Full Day and Night Closed-Loop With DiAs Platform

NCT02147860

TERMINATED Phase 2

Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma

NCT02111785

COMPLETED NA

Study of Airflow in the Lungs Using Helium MRI

NCT02154568

TERMINATED Early Phase 1

Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer

NCT01962909

COMPLETED

RNA Cloning and Visualization in Human Atherosclerosis

NCT01928095

COMPLETED NA

Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic

NCT02111772

COMPLETED NA

A Mindfulness Based Application for Smoking Cessation

NCT01982110

COMPLETED NA

Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents

NCT01890954

COMPLETED NA

Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study

NCT01973413

COMPLETED NA

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

NCT01839370

COMPLETED NA

Insertion Technique in Large Volume Paracentesis

NCT02310165

COMPLETED Phase 2

Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication

NCT01890135

COMPLETED

Response of Pulse Pressure Variation in PA Catheter Tracing to IV Fluid Bolus in the ICU

NCT02419404

COMPLETED NA

Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations

NCT02432391

COMPLETED NA

Biobehavioral Mechanisms of Glucose Variability

NCT01835964

TERMINATED

Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management

NCT01767831

COMPLETED Phase 2

Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus

NCT02388997

COMPLETED

Validation of Peripheral Pressure Volume Loops and Ultrasound-derived "Cardiac Power" by Comparison With Invasive Left Ventricular Pressure Volume Loops

NCT01750450

COMPLETED

Validation of Pulse Wave Doppler Demodulation Algorithm for the Continuous, Non-invasive Measurement of Blood Flow Velocity

NCT01750125

COMPLETED NA

Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections

NCT01886001

COMPLETED NA

Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy

NCT01714505

COMPLETED NA

Evaluating and Improving Functional Driving Vision of Patients With Astigmatism

NCT02624791

COMPLETED NA

Use of Near Infrared Spectroscopy to Measure Intracranial ScvO2

NCT01746576

COMPLETED NA

Lung Cancer Information Study (LCIS-R01)

NCT01924416

COMPLETED

Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes

NCT01653210

COMPLETED NA

Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)

NCT01669603

COMPLETED Phase 4

Study of Dexmedetomidine in Spine Surgery

NCT01850017

COMPLETED NA

Mindfulness-Based Relapse Prevention for Alcohol Use Disorders in Remission

NCT02147483

COMPLETED NA

Development and Feasibility of an Internet Intervention for Adults With Spinal Cord Injury to Prevent Pressure Ulcers

NCT01885962

COMPLETED NA

Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker

NCT01582139

TERMINATED Phase 1

Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006)

NCT01602679

COMPLETED Phase 3

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

NCT01369069

COMPLETED NA

Outpatient Control-to-Range: System and Monitoring Testing

NCT01578980

TERMINATED Phase 2

Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

NCT01617213

COMPLETED Phase 2

Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma

NCT01524692

COMPLETED NA

Oral Immunotherapy for Peanut and Mammalian Meat Allergies

NCT02350660

COMPLETED NA

Identifying Driving Risk Factors in Type 1 Diabetes and Their Reduction Via Internet Program (DiabetesDriving.Com)

NCT01563887

COMPLETED Early Phase 1

Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer

NCT01482728

TERMINATED Phase 2

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

NCT01622556

← Previous Page 7 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 58
Phase 2 51
Phase 3 14
Phase 4 26

What is open in the University of Virginia pipeline

101 recruiting of 449 indexed (22% open); 281 completed (63%).

Phase mix: 40 late (III/IV) vs 109 early (I/II) (early-phase heavy).

Top condition: Type 1 Diabetes Mellitus (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Virginia: open-pipeline peers nationwide

Peers matched on 449 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 5%10%15%20%25% Total trials Recruiting share University of VirginiaMedical College of WisconsinAlliance for Clinical Trials in OncologyBoston Children's HospitalChildren's Hospital of PhiladelphiaOhio State University Comprehensive Cancer CenterUniversity of DelawareUniversity of OklahomaALX Oncology
University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 449 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

What to do with this University of Virginia page

449 registered trials is a research-attention snapshot, not an endorsement of University of Virginia or any single study.

  • 101 of University of Virginia's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Type 1 Diabetes Mellitus is the condition University of Virginia studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Virginia pipeline card: 449 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.